Logo Image
Opinion|Videos|April 25, 2025

Exploring Novel Options for the Management of Uncomplicated UTIs

Panelists discuss how sulopenem etzadroxil/probenecid, approved in October 2024, functions as an oral β-lactam/β-lactamase inhibitor effective against extended-spectrum β-lactamase producers per SURE 1 and REASSURE trial findings whereas gepotidacin works through a novel mechanism as a triazaacenaphthylene bacterial topoisomerase inhibitor targeting resistant pathogens via unique DNA gyrase and topoisomerase IV binding sites, with EAGLE trial findings demonstrating noninferiority to nitrofurantoin with approximately 90% cure rates.

Episodes in this series

Video content above is prompted by the following:

  • In October 2024, sulopenem etzadroxil/probenecid received FDA approval for uncomplicated urinary tract infection (UTI) based on the SURE 1 and REASSURE data. What is the mechanism of action of this therapy, and what are some key efficacy and safety points to be shared?
  • Another emerging therapy showing promise in addressing patients with recurrent UTIs is gepotidacin, based on the EAGLE-2 and EAGLE-3trial findings. How is gepotidacin’s mechanism of action different from the other 2 newly approved therapies?

What are some key points to share regarding the methodology and outcomes of the EAGLE trials?

Related Content